Virginia Retirement Systems ET AL Raises Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Virginia Retirement Systems ET AL lifted its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating) by 126.6% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,500 shares of the medical research company’s stock after purchasing an additional 17,600 shares during the period. Virginia Retirement Systems ET AL’s holdings in Bio-Rad Laboratories were worth $17,742,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of BIO. Two Sigma Advisers LP increased its stake in shares of Bio-Rad Laboratories by 326.1% during the 3rd quarter. Two Sigma Advisers LP now owns 1,568 shares of the medical research company’s stock worth $1,170,000 after purchasing an additional 1,200 shares in the last quarter. Captrust Financial Advisors increased its stake in shares of Bio-Rad Laboratories by 6.2% during the 3rd quarter. Captrust Financial Advisors now owns 686 shares of the medical research company’s stock worth $512,000 after purchasing an additional 40 shares in the last quarter. Stonnington Group LLC increased its stake in shares of Bio-Rad Laboratories by 101.1% during the 4th quarter. Stonnington Group LLC now owns 2,136 shares of the medical research company’s stock worth $1,442,000 after purchasing an additional 1,074 shares in the last quarter. State of Alaska Department of Revenue boosted its position in Bio-Rad Laboratories by 103.8% during the fourth quarter. State of Alaska Department of Revenue now owns 16,966 shares of the medical research company’s stock worth $12,818,000 after acquiring an additional 8,641 shares during the last quarter. Finally, Contravisory Investment Management Inc. acquired a new stake in Bio-Rad Laboratories during the fourth quarter worth approximately $605,000. 63.66% of the stock is owned by institutional investors and hedge funds.

BIO has been the topic of a number of analyst reports. TheStreet lowered shares of Bio-Rad Laboratories from a “b-” rating to a “c+” rating in a research report on Thursday, April 28th. Citigroup decreased their target price on shares of Bio-Rad Laboratories from $800.00 to $750.00 in a research report on Monday, May 2nd. Jefferies Financial Group restated a “buy” rating and set a $700.00 target price on shares of Bio-Rad Laboratories in a research report on Friday, April 29th. Finally, StockNews.com initiated coverage on shares of Bio-Rad Laboratories in a research report on Thursday, March 31st. They set a “hold” rating on the stock. One equities research analyst has rated the stock with a hold rating and three have given a buy rating to the company. Based on data from MarketBeat.com, Bio-Rad Laboratories currently has an average rating of “Moderate Buy” and a consensus price target of $793.33.

Shares of BIO opened at $502.34 on Friday. The firm has a market cap of $15.04 billion, a PE ratio of -102.94 and a beta of 0.93. The company’s fifty day moving average is $506.33 and its two-hundred day moving average is $577.91. Bio-Rad Laboratories, Inc. has a fifty-two week low of $462.61 and a fifty-two week high of $832.70. The company has a quick ratio of 4.16, a current ratio of 5.10 and a debt-to-equity ratio of 0.12.

Bio-Rad Laboratories (NYSE:BIOGet Rating) last announced its quarterly earnings results on Thursday, April 28th. The medical research company reported $4.94 earnings per share for the quarter, beating analysts’ consensus estimates of $2.80 by $2.14. The company had revenue of $700.10 million for the quarter, compared to analyst estimates of $678.00 million. Bio-Rad Laboratories had a negative net margin of 3.49% and a positive return on equity of 3.66%. Bio-Rad Laboratories’s revenue for the quarter was down 3.7% on a year-over-year basis. During the same quarter last year, the business earned $5.21 EPS. As a group, equities research analysts anticipate that Bio-Rad Laboratories, Inc. will post 14.2 earnings per share for the current year.

About Bio-Rad Laboratories (Get Rating)

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.

Further Reading

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIOGet Rating).

Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)

Receive News & Ratings for Bio-Rad Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Rad Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.